{"id":"NCT03355209","sponsor":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","briefTitle":"A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome","officialTitle":"A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults With LGS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-27","primaryCompletion":"2024-05-23","completion":"2024-05-23","firstPosted":"2017-11-28","resultsPosted":"2025-07-03","lastUpdate":"2025-07-03"},"enrollment":296,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lennox Gastaut Syndrome"],"interventions":[{"type":"DRUG","name":"ZX008 0.2 or 0.8 mg/kg/day","otherNames":[]},{"type":"DRUG","name":"Matching Placebo","otherNames":["Placebo Comparator"]}],"arms":[{"label":"ZX008 0.2 or 0.8 mg/kg/day","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open-Label","type":"EXPERIMENTAL"}],"summary":"This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).","primaryOutcome":{"measure":"Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo Group","timeFrame":"From Baseline up to 14 weeks [Titration Period (2 weeks) + Maintenance Period (12 weeks)]","effectByArm":[{"arm":"Cohort A: Placebo","deltaMin":-7.59,"sd":null},{"arm":"Cohort A: ZX008 0.8 mg/kg/Day","deltaMin":-26.49,"sd":null},{"arm":"Cohort B: Placebo","deltaMin":-17.89,"sd":null},{"arm":"Cohort B: ZX008 0.8 mg/kg/Day","deltaMin":-34.52,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0008"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":72,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Italy","Japan","Mexico","Netherlands","Poland","Spain","Sweden"]},"refs":{"pmids":["35499850"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":87},"commonTop":["Decreased appetite","Somnolence","Fatigue","Pyrexia","Nasopharyngitis"]}}